Title: 4 A JOINT RESOLUTION OF THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF
Official Title: 4 A JOINT RESOLUTION OF THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF
Number of Sections: 1
Source: versions - SJ0050_1(1).pdf
Media Type: application/pdf
Strikethrough Detection: 2 sections found

================================================================================

Section 1:
69th Legislature SJ 50.1
1 SENATE JOINT RESOLUTION NO. 50
2 INTRODUCED BY B. USHER
3
5 MONTANA REQUESTING AN INTERIM STUDY OF THE SHORT-TERM AND LONG-TERM EFFECTS OF
6 THE MEDICAL RESPONSE TO COVID-19; AND REQUIRING THAT THE FINAL RESULTS OF THE STUDY
7 BE REPORTED TO THE 70TH LEGISLATURE.
8
9 WHEREAS, the federal government impelled the use of vaccines, remdesivir, dexamethasone, and
10 certain other treatments as part of the national response to COVID-19; and
11 WHEREAS, the federal government incentivized providers to diagnose their patients with COVID-19
12 and to prescribe the treatments pushed by the federal government; and
13 WHEREAS, these incentives compromised patient health, medical freedom, and the patient-provider
14 relationship through inaccurate diagnoses and a limited menu of treatment options, many of which caused
15 irreversible harm.
16
17 NOW, THEREFORE, BE IT RESOLVED BY THE SENATE AND THE HOUSE OF REPRESENTATIVES OF
18 THE STATE OF MONTANA:
19 That the Legislative Council be requested to designate an appropriate interim committee or statutory
20 committee, pursuant to section 5-5-217, MCA, or direct sufficient staff resources to review the short-term and
21 long-term effects of:
22 (1) the COVID-19 vaccine;
23 (2) remdesivir and dexamethasone; and
24 (3) other questionable drugs and treatments used to treat COVID-19.
25 BE IT FURTHER RESOLVED, that the study examine the benefits of ivermectin as a treatment for
26 COVID-19.
27 BE IT FURTHER RESOLVED, that the study examine the outcomes of the Montana Right to Try Act
28 related to experimental and innovative treatments for both active infections of COVID-19 and health issues that
- 1 - Authorized Print Version – SJ 50
69th Legislature SJ 50.1
1 impact individuals after infection with COVID-19, colloquially called "long COVID", and experimental treatments
2 to mitigate the negative impacts of the COVID-19 vaccines and federally recommended treatments of COVID-
3 19.
4 BE IT FURTHER RESOLVED, that if the study is assigned to staff, any findings or conclusions be
5 presented to and reviewed by an appropriate committee designated by the Legislative Council.
6 BE IT FURTHER RESOLVED, that all aspects of the study, including presentation and review
7 requirements, be concluded prior to September 15, 2026.
8 BE IT FURTHER RESOLVED, that the final results of the study, including any findings, conclusions,
9 comments, or recommendations of the appropriate committee, be reported to the 70th Legislature.
10 - END -
- 2 - Authorized Print Version – SJ 50
[DELETED: eS- SIAMTBW0c1W2a3W4r5i7N8T9T0c1l2()t3()r4()o5B6C7B8r]
[DELETED: eS- it1BpBrBc0-]


================================================================================

Raw Text:
69th Legislature SJ 50.1
1 SENATE JOINT RESOLUTION NO. 50
2 INTRODUCED BY B. USHER
3
4 A JOINT RESOLUTION OF THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF
5 MONTANA REQUESTING AN INTERIM STUDY OF THE SHORT-TERM AND LONG-TERM EFFECTS OF
6 THE MEDICAL RESPONSE TO COVID-19; AND REQUIRING THAT THE FINAL RESULTS OF THE STUDY
7 BE REPORTED TO THE 70TH LEGISLATURE.
8
9 WHEREAS, the federal government impelled the use of vaccines, remdesivir, dexamethasone, and
10 certain other treatments as part of the national response to COVID-19; and
11 WHEREAS, the federal government incentivized providers to diagnose their patients with COVID-19
12 and to prescribe the treatments pushed by the federal government; and
13 WHEREAS, these incentives compromised patient health, medical freedom, and the patient-provider
14 relationship through inaccurate diagnoses and a limited menu of treatment options, many of which caused
15 irreversible harm.
16
17 NOW, THEREFORE, BE IT RESOLVED BY THE SENATE AND THE HOUSE OF REPRESENTATIVES OF
18 THE STATE OF MONTANA:
19 That the Legislative Council be requested to designate an appropriate interim committee or statutory
20 committee, pursuant to section 5-5-217, MCA, or direct sufficient staff resources to review the short-term and
21 long-term effects of:
22 (1) the COVID-19 vaccine;
23 (2) remdesivir and dexamethasone; and
24 (3) other questionable drugs and treatments used to treat COVID-19.
25 BE IT FURTHER RESOLVED, that the study examine the benefits of ivermectin as a treatment for
26 COVID-19.
27 BE IT FURTHER RESOLVED, that the study examine the outcomes of the Montana Right to Try Act
28 related to experimental and innovative treatments for both active infections of COVID-19 and health issues that
- 1 - Authorized Print Version – SJ 50

69th Legislature SJ 50.1
1 impact individuals after infection with COVID-19, colloquially called "long COVID", and experimental treatments
2 to mitigate the negative impacts of the COVID-19 vaccines and federally recommended treatments of COVID-
3 19.
4 BE IT FURTHER RESOLVED, that if the study is assigned to staff, any findings or conclusions be
5 presented to and reviewed by an appropriate committee designated by the Legislative Council.
6 BE IT FURTHER RESOLVED, that all aspects of the study, including presentation and review
7 requirements, be concluded prior to September 15, 2026.
8 BE IT FURTHER RESOLVED, that the final results of the study, including any findings, conclusions,
9 comments, or recommendations of the appropriate committee, be reported to the 70th Legislature.
10 - END -
- 2 - Authorized Print Version – SJ 50

[DELETED: eS- SIAMTBW0c1W2a3W4r5i7N8T9T0c1l2()t3()r4()o5B6C7B8r]
[DELETED: eS- it1BpBrBc0-]